Avivagen Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- G. F. Kym Anthony
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 100 Sussex Drive Ottawa ON Canada K1A 0R6
- IPO Date
- May 2, 2013
- Website
- avivagen.com
- Similar Companies
- Business
- Avivagen Inc. (VIVXF) is a Canada-based life sciences company that develops and commercializes health products for livestock, companion animals and humans utilizing its proprietary OxC-beta technology, a first-in-class source of beta-carotene-oxygen copolymer compounds offering non-vitamin A benefits such as enhanced immune function, improved growth performance and reduced reliance on antibiotics in animal feeds; core products include OxC-beta Livestock for swine, poultry and dairy applications, Vivamune Vital Health Chews and Oximunol Chewable Tablets for companion animals. Founded in 2005 and headquartered at 100 Sussex Drive in Ottawa, Ontario, the company operates primarily in North America with distribution and trials extending to Australia, Brazil, Mexico and other regions in the Americas, targeting livestock producers, pet owners and potentially human wellness markets through its biotechnology platform. Recent developments include board changes in 2023 with David Hankinson appointed as Chair and Kym Anthony as Vice-Chair following the departure of Jeffrey Kraws and Aubrey Dan, alongside ongoing commercial expansions such as a 1.2-tonne order from AB Vista for poultry and cattle trials in Brazil, dairy sector agreements in Mexico demonstrating improved milk quality, and cumulative usage of OxC-beta in approximately 16 million piglets, 94,000 sows, 19.6 million poultry and 12,000 dairy cows as of mid-2022, though the company faced financial challenges including a voluntary assignment into bankruptcy proceedings announced around 2023-2024.
High Tide (NASDAQ:HITI) and Avivagen (OTCMKTS:VIVXF) Financial Comparison
Contrasting Avivagen (OTCMKTS:VIVXF) & Stryker (NYSE:SYK)
Avivagen Makes Voluntary Assignment into Bankruptcy Under the BIA
Avivagen Announces New 500Kg Order for OxC-beta™
Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2023
Avivagen Provides Corporate Updates
Avivagen Announces New Orders for 1.1 Tonnes of Oxc-Beta™ Livestock Product
Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants
Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2021
Avivagen Announces Largest Single Customer Purchase Order
Avivagen Inc. to Issue Shares to Holders of Debentures in Lieu of Annual Maintenance Fee
Avivagen Discusses Significant Purchase Orders for OxC-beta(TM) Livestock with The Stock Day Podcast